Investing.com -- Cassava Sciences, Inc. (NASDAQ: SAVA )宣布获得其候选药物simufilam的一项治疗方法专利独家许可后，公司股价上涨7%。该专利涉及罕见神经发育障碍相关癫痫的潜在治疗方法，包括结节性硬化症（TSC）。

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug candidate, simufilam. The ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...